### Highlights of This Issue 2503

#### SPECIAL FEATURES

**CCR Translations**

- **2505** Minimal Residual Disease in Breast Cancer: In Blood Veritas
  Giulia Siravegna and Alberto Bardelli
  *See related article, p. 2643*

**Molecular Pathways**

- **2508** Molecular Pathways: Preclinical Models and Clinical Trials with Metformin in Breast Cancer
  Alastair M. Thompson

- **2516** Molecular Pathways: Adaptive Kinome Reprogramming in Response to Targeted Inhibition of the BRAF–MEK–ERK Pathway in Cancer
  Gary L. Johnson, Timothy J. Stuhlmiller, Steven P. Angus, Jon S. Zawistowski, and Lee M. Graves

**CCR Focus**

- **2524** The Language of Pharmacodynamics
  Susan E. Bates

- **2525** Pharmacologic Biomarkers in the Development of Stratified Cancer Medicine
  William Douglas Figg and David R. Newell

- **2530** Using Pharmacogene Polymorphism Panels to Detect Germline Pharmacodynamic Markers in Oncology
  Daniel L. Hertz and Howard L. McLeod

- **2541** Genome-Wide Association Study: A Useful Tool to Identify Common Genetic Variants Associated with Drug Toxicity and Efficacy in Cancer Pharmacogenomics
  Siew-Kee Low, Atsushi Takahashi, Taisei Mushiroda, and Michiaki Kubo

- **2553** Circulating Tumor Cells: A Multifunctional Biomarker
  Timothy A. Yap, David Lorente, Aurelius Omlin, David Olmos, and Johann S. de Bono

**Implementing Validated Pharmacodynamic Assays in Multiple Laboratories: Challenges, Successes, and Limitations**

- **2569** In Vivo Imaging as a Pharmacodynamic Marker
  Astrid A.M. van der Veldt and Adriaan A. Lammertsma

- **2578** Pharmacodynamic Biomarkers: Falling Short of the Mark?
  Justin F. Gainor, Dan L. Longo, and Bruce A. Chabner

### HUMAN CANCER BIOLOGY

- **2595** FOXM1 Promotes the Warburg Effect and Pancreatic Cancer Progression via Transactivation of LDHA Expression
  Jijie Cui, Min Shi, Dacheng Xie, Daoyan Wei, Zhiliang Jia, Shaojiang Zheng, Yong Gao, Suyun Huang, and Keping Xie

- **2607** Human Melanoma Metastases Demonstrate Nonstochastic Site-Specific Antigen Heterogeneity That Correlates with T-cell Infiltration
  Edmund K. Bartlett, Patricia A. Fetsch, Armando C. Filie, Andrea Abati, Seth M. Steinberg, John R. Wunderlich, Donald E. White, Daniel J. Stephens, Francesco M. Marincola, Steven A. Rosenberg, and Udai S. Kammula

- **2617** miR-141 Is a Key Regulator of Renal Cell Carcinoma Proliferation and Metastasis by Controlling EphA2 Expression
  Xuan Yu Chen, Xiaogang Wang, Anming Ruan, Weiwei Han, Yan Zhao, Xiang Lu, Pei Xiao, Hangchuan Shi, Rong Wang, Li Chen, Shaoyong Chen, Quansheng Du, Hongmei Yang, and Xiaoping Zhang

- **2631** Regulation of Colorectal Carcinoma Stemness, Growth, and Metastasis by an miR-200c-Sox2-Negative Feedback Loop Mechanism
  Yan-Xia Lu, Li Yuan, Xiao-Lei Xue, Min Zhou, Yan Liu, Chao Zhang, Jing-Ping Li, Lin Zheng, Min Hong, and Xue-Nong Li
### Table of Contents

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2761</td>
<td>A Signature Predicting Poor Prognosis in Gastric and Ovarian Cancer Represents a Coordinated Macrophage and Stromal Response</td>
<td>Rita A. Busuttil, Joshy George, Richard W. Tothill, Kylie Ioculano, Adam Kowalczyk, Catherine Mitchell, Stephen Lade, Patrick Tan, Izhak Haviv, and Alex Boussioutas</td>
</tr>
<tr>
<td>2773</td>
<td>In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas</td>
<td>Kurt A. Schalper, Vamsidhar Velcheti, Daniel Carvajal, Hallie Wimberly, Jason Brown, Lajos Pusztai, and David L. Rimm</td>
</tr>
</tbody>
</table>

**CANCER THERAPY: CLINICAL**

| 2793 | A Pharmacodynamic/Pharmacokinetic Study of Ficlatuzumab in Patients with Advanced Solid Tumors and Liver Metastases | Josep Tabernero, Maria Elena Elez, Maria Herranz, Isabel Rico, Ludmila Prudkin, Jordi Andreu, Jose Mateos, Maria Josep Carreras, May Han, James Gifford, Marc Credi, Wei Yin, Shelali Agarwal, Philip Komarnitsky, and Jose Baselga |

**PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE**

| 2805 | Quantitative Measurements of Tumoral p95HER2 Protein Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab: Independent Validation of the p95HER2 Clinical Cutoff | Renata Duchnowska, Jeff Sperinde, Ahmed Chenna, Mojgan Haddad, Agnes Paquet, Yolanda Lie, Jodi M. Weidler, Weidong Huang, John Winslow, Tomasz Jankowski, Bogumila Czartoryska-Arthukowicz, Piotr J. Wycocki, Małgorzata Foszczyńska-Kłoda, Barbara Radecka, Maria M. Litwiniiuk, Jolanta Żok, Michał Wiśniewski, Dorota Zuziak, Wojciech Biernat, and Jacek Jassem |

**AC icon indicates Author Choice**

**CME icon indicates that this article is available for continuing medical education credit at http://cme.aacrjournals.org**

For more information please visit www.aacrjournals.org

**ABOUT THE COVER**

The cover shows a brain section from a mouse injected with a brain seeking variant of the human breast cancer cell line MDA-MB-231. Immunohistochemical staining indicates a lack of MGMT expression in the tumor cells. Tissue was stained with anti-MGMT antibody and counterstained with hematoxylin and eosin. For details, see the article by Palmieri and colleagues on page 2727 of this issue.